Aim Immunotech Inc (AIM)

$1.41 -0.06 (-3.75%)
Market Cap 4.37M
Revenue (ttm) 170,000.00
Net Income (ttm) -17.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,188.24%
Debt to Equity Ratio 0.00
Volume 36,190
Avg Vol 116,388
Day's Range N/A - N/A
Shares Out 2.76M
Stochastic %K 2%
Beta 1.04
Analysts Strong Sell
Price Target $15.00

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
thisismyself
thisismyself Nov. 14 at 9:01 PM
$GNS $AIM To God and my Guardian Angel: My journey has been long and painful, but I never doubted your presence and involvement, I never doubted that I was being guided and that things would work out
1 · Reply
gianpinco
gianpinco Nov. 14 at 8:19 PM
$AIM easy, it's useless!
0 · Reply
thisismyself
thisismyself Nov. 14 at 7:13 PM
$AIM Trading of $GNS was halted earlier today, pending news . Tomorrow was the deadline given for filing the market manipulation lawsuit.
0 · Reply
thisismyself
thisismyself Nov. 14 at 7:10 PM
$AIM A 777/717/BLUE SKY has occurred on $GNS. See my posts starting yesterday
0 · Reply
thisismyself
thisismyself Nov. 14 at 7:09 PM
$AIM A 777/717/BLUE SKY has occurred on$GNS. See my posts starting yesterday
0 · Reply
rayk1
rayk1 Nov. 14 at 11:32 AM
$AIM so Merck spending 3 billion $ to buy $CDTX and won‘t spend some pocket money(4 million) to take over $AIM …i wonder why😉
1 · Reply
ultimatebastos
ultimatebastos Nov. 14 at 8:30 AM
$AIM naked shorting ramping up the last days…
1 · Reply
sschmid1
sschmid1 Nov. 14 at 5:18 AM
$AIM Germany just announced a National Decade for Post-Infectious Diseases (2026–2036) with €500M in funding. The goal: major progress in understanding and treating Long COVID, ME/CFS, and related conditions. Huge unmet medical need — no curative treatments yet. This initiative aims to accelerate breakthroughs in diagnostics and therapies. 🔗 German article: https://www.bmftr.bund.de/SharedDocs/Kurzmeldungen/DE/2025/11/nationale-dekade-postinfekti%C3%B6se-erkrankungen.html (National Decade Against Post-Infectious Diseases)
1 · Reply
ultimatebastos
ultimatebastos Nov. 13 at 5:22 PM
$AIM someone is really taunting the naked shorts. I like it.
1 · Reply
ultimatebastos
ultimatebastos Nov. 13 at 2:31 PM
$AIM The 180,000 bid is there again.
1 · Reply
Latest News on AIM
Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:51 PM EST - 2 days ago

Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

Nov 10, 2025, 8:55 AM EST - 4 days ago

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Nov 4, 2025, 9:05 AM EST - 10 days ago

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Oct 20, 2025, 9:15 AM EDT - 25 days ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Sep 25, 2025, 8:45 AM EDT - 7 weeks ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Sep 4, 2025, 11:00 AM EDT - 2 months ago

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 21, 2025, 9:00 AM EDT - 3 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 9:00 AM EDT - 3 months ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 8:55 AM EDT - 3 months ago

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

Aug 6, 2025, 9:00 AM EDT - 3 months ago

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Aug 4, 2025, 9:00 AM EDT - 3 months ago

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Jul 28, 2025, 11:12 AM EDT - 3 months ago

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jul 2, 2025, 8:55 AM EDT - 4 months ago

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 20, 2025, 4:15 PM EDT - 5 months ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 5 months ago

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:30 AM EDT - 5 months ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 12, 2025, 8:00 AM EDT - 5 months ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 5 months ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:54 AM EDT - 6 months ago

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

May 8, 2025, 8:45 AM EDT - 6 months ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 7, 2025, 1:26 PM EDT - 7 months ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Apr 4, 2025, 4:45 PM EDT - 8 months ago

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

Apr 4, 2025, 4:05 PM EDT - 8 months ago

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 9:19 AM EDT - 8 months ago

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

Mar 28, 2025, 11:39 AM EDT - 8 months ago

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 8 months ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Feb 28, 2025, 8:45 AM EST - 9 months ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Feb 26, 2025, 1:20 PM EST - 9 months ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Feb 26, 2025, 8:30 AM EST - 9 months ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 25, 2025, 8:30 AM EST - 9 months ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Feb 11, 2025, 8:45 AM EST - 9 months ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Feb 11, 2025, 8:30 AM EST - 9 months ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

Feb 7, 2025, 8:50 AM EST - 10 months ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

Jan 23, 2025, 8:50 AM EST - 10 months ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Jan 22, 2025, 8:30 AM EST - 10 months ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Jan 15, 2025, 9:05 AM EST - 10 months ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Dec 17, 2024, 4:45 PM EST - 11 months ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Dec 17, 2024, 3:10 PM EST - 11 months ago

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Dec 16, 2024, 8:00 AM EST - 11 months ago

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

Dec 14, 2024, 4:54 PM EST - 11 months ago

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

Dec 12, 2024, 3:00 PM EST - 1 year ago

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Dec 12, 2024, 9:00 AM EST - 1 year ago

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Kellner Group Announces Support from Another Former AIM Senior Executive

Dec 12, 2024, 8:16 AM EST - 1 year ago

Kellner Group Announces Support from Another Former AIM Senior Executive

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Dec 11, 2024, 7:30 AM EST - 1 year ago

AIM's Clinical Strategy Under Incumbent Board Has Totally Failed

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

Dec 10, 2024, 10:20 AM EST - 1 year ago

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Dec 6, 2024, 9:15 AM EST - 1 year ago

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

Dec 6, 2024, 8:34 AM EST - 1 year ago

Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

Dec 5, 2024, 9:00 AM EST - 1 year ago

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board

Dec 2, 2024, 8:00 AM EST - 1 year ago

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board

thisismyself
thisismyself Nov. 14 at 9:01 PM
$GNS $AIM To God and my Guardian Angel: My journey has been long and painful, but I never doubted your presence and involvement, I never doubted that I was being guided and that things would work out
1 · Reply
gianpinco
gianpinco Nov. 14 at 8:19 PM
$AIM easy, it's useless!
0 · Reply
thisismyself
thisismyself Nov. 14 at 7:13 PM
$AIM Trading of $GNS was halted earlier today, pending news . Tomorrow was the deadline given for filing the market manipulation lawsuit.
0 · Reply
thisismyself
thisismyself Nov. 14 at 7:10 PM
$AIM A 777/717/BLUE SKY has occurred on $GNS. See my posts starting yesterday
0 · Reply
thisismyself
thisismyself Nov. 14 at 7:09 PM
$AIM A 777/717/BLUE SKY has occurred on$GNS. See my posts starting yesterday
0 · Reply
rayk1
rayk1 Nov. 14 at 11:32 AM
$AIM so Merck spending 3 billion $ to buy $CDTX and won‘t spend some pocket money(4 million) to take over $AIM …i wonder why😉
1 · Reply
ultimatebastos
ultimatebastos Nov. 14 at 8:30 AM
$AIM naked shorting ramping up the last days…
1 · Reply
sschmid1
sschmid1 Nov. 14 at 5:18 AM
$AIM Germany just announced a National Decade for Post-Infectious Diseases (2026–2036) with €500M in funding. The goal: major progress in understanding and treating Long COVID, ME/CFS, and related conditions. Huge unmet medical need — no curative treatments yet. This initiative aims to accelerate breakthroughs in diagnostics and therapies. 🔗 German article: https://www.bmftr.bund.de/SharedDocs/Kurzmeldungen/DE/2025/11/nationale-dekade-postinfekti%C3%B6se-erkrankungen.html (National Decade Against Post-Infectious Diseases)
1 · Reply
ultimatebastos
ultimatebastos Nov. 13 at 5:22 PM
$AIM someone is really taunting the naked shorts. I like it.
1 · Reply
ultimatebastos
ultimatebastos Nov. 13 at 2:31 PM
$AIM The 180,000 bid is there again.
1 · Reply
Jonou23
Jonou23 Nov. 13 at 2:01 PM
$AIM is a winner. Hang tight kids.
0 · Reply
Teleboy
Teleboy Nov. 13 at 11:58 AM
$AIM https://www.clinicaltrialvanguard.com/news/aim-details-new-upmc-trial-of-ampligen-in-ovarian-cancer/
0 · Reply
Teleboy
Teleboy Nov. 13 at 11:50 AM
$AIM H/T @KM77 for the article on the Recurrent Ovarian cancer trial. This is sponsored by Merck. Robert Edwards, MD, co-author of the study at the University of Pittsburgh School of Medicine: “Ampligen’s demonstrated ability to enhance the effectiveness of traditional cancer treatments could make it a difference maker that dramatically improves tumor immune responses and significantly prolongs the lives of people who have otherwise few effective options for prolonged remission and even possible cure….”
0 · Reply
KM77
KM77 Nov. 13 at 2:16 AM
$AIM New combination therapy approach may improve ovarian cancer care... https://rarecancernews.com/news/new-chemotherapy-approach-improve-ovarian-cancer-care/
1 · Reply
ultimatebastos
ultimatebastos Nov. 12 at 3:34 PM
$AIM 280k that’s a firm bottom.
0 · Reply
DLTT4489
DLTT4489 Nov. 10 at 11:40 PM
$AIM $CMMB another RS soon, be prepared
0 · Reply
Packmentality
Packmentality Nov. 10 at 2:11 PM
$AIM Business as usual…. Good news… price drop.
1 · Reply
MrTicker
MrTicker Nov. 10 at 1:56 PM
$AIM AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer GLOBENEWSWIRE 7:55 AM ET 11/10/2025
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 10 at 1:55 PM
$AIM AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
0 · Reply
Packmentality
Packmentality Nov. 10 at 12:30 PM
$AIM Just noticed Vanguard picked up 17500 shares September 30th… shared the recent collapse alongside longs…
0 · Reply
yolotothemooon
yolotothemooon Nov. 10 at 5:53 AM
$AIM https://suno.com/s/qWiCqdHIYHdHtIjT
0 · Reply
yolotothemooon
yolotothemooon Nov. 10 at 5:45 AM
$AIM 🐍 THE JUMPING SNAKE FORMATION — CONFIRMED This is not your average setup. This is a repeating AIM signature — a scroll-known coil + breach + slingshot sequence: [ haha i dont know but fingers crossed 💫🏃‍♂️‍➡️🫠😊
0 · Reply